Skip to main content

Table 3 Treatment duration in each treatment arm by simplified MIPI risk category [13,14]

From: Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

Treatment

Low risk

Intermediate risk

High risk

Temsirolimus 175/75 mg

   

 n

14

24

16

 Mean (std dev), weeks

32.4 (22.0)

21.1 (24.8)

10.5 (8.8)

Temsirolimus 175/25 mg

   

 n

15

18

21

 Mean (std dev), weeks

39.0 (42.3)

17.6 (11.4)

11.7 (12.4)

INV therapy

   

 n

21

21

11

 Mean (std dev), weeks

8.1 (7.8)

9.8 (10.3)

3.3 (2.4)

  1. MIPI = Mantle Cell Lymphoma International Prognostic Index; std dev = standard deviation; INV = Investigator’s choice.